VIYASHViyash Scientific Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Viyash Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides finished dosage formulation in therapeutic areas, such as nutrition, pain management, parasite control, antibiotics, and gut health for livestock, poultry, and companion animals. It also offers analytical services; and VET formulation services. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on VIYASH — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 186.6% YoY
- • Debt/Equity: 0.16
- • Promoter holding: 67.9%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month vs NIFTY: +6.1% relative
Bull case
- • Profit growth: 186.6% YoY
- • Debt/Equity: 0.16
- • Promoter holding: 67.9%
- • Price vs SMA200: above
Bear case
- • Revenue growth: -50.5% YoY
- • ROE: 7.9%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Revenue growth: -50.5% YoY
- • ROE: 7.9%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹8.79). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.